Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Altimmune (NASDAQ:ALT) posted its earnings results on Wednesday. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02, FiscalAI reports. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%.

Here are the key takeaways from Altimmune’s conference call:

• PERFORMA Phase III in MASH has begun enrolling across approximately 300 global sites, with management targeting the faster end of an 18–24-month enrollment window. The company expects the 52-week data readout in 2029.
• Pemvidutide produced statistically significant and clinically meaningful results in the RECLAIM Phase II alcohol use disorder trial, reducing heavy drinking days and improving key FDA-recognized measures including WHO risk-level reductions and zero heavy drinking days.
• Altimmune plans to seek an FDA end-of-Phase II meeting for AUD and believes a single global Phase III trial could satisfy U.S. and European requirements. Management is also evaluating inclusion of patients with BMI below 25, lower-dose options, and AUD patients with overlapping alcohol-related liver disease.
• Enrollment is complete in the approximately 120-patient RESTORE trial for alcohol-related liver disease, with top-line results expected in the second half of 2027. The amended analysis will assess liver stiffness at both 48 and 24 weeks to better characterize pemvidutide’s potential liver benefit.
• Altimmune ended June with approximately $519 million in cash, providing a runway through the MASH Phase III 52-week readout, but the balance does not fund a potential AUD Phase III program. The company expects to pursue non-dilutive financing such as partnerships, debt, or royalties rather than relying primarily on additional equity.

Altimmune Price Performance

Shares of NASDAQ ALT traded up $0.16 during midday trading on Wednesday, hitting $3.16. The stock had a trading volume of 3,143,173 shares, compared to its average volume of 4,343,375. The company has a quick ratio of 29.56, a current ratio of 29.56 and a debt-to-equity ratio of 0.12. The stock has a 50 day simple moving average of $2.90 and a 200-day simple moving average of $3.44. The company has a market capitalization of $614.54 million, a PE ratio of -3.40 and a beta of 0.27. Altimmune has a 1 year low of $2.56 and a 1 year high of $6.44.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Citizens Jmp lowered their price target on Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 14th. HC Wainwright restated a “buy” rating on shares of Altimmune in a research report on Tuesday, July 28th. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research note on Tuesday, June 2nd. Wall Street Zen raised shares of Altimmune from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a report on Wednesday, June 24th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Altimmune presently has an average rating of “Moderate Buy” and an average price target of $15.71.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ALT. Virtu Financial LLC boosted its stake in Altimmune by 21.7% during the 4th quarter. Virtu Financial LLC now owns 58,477 shares of the company’s stock worth $211,000 after purchasing an additional 10,409 shares during the last quarter. Invesco Ltd. raised its position in shares of Altimmune by 32.7% in the fourth quarter. Invesco Ltd. now owns 214,824 shares of the company’s stock valued at $776,000 after buying an additional 52,881 shares during the last quarter. Vines Capital Management LLC acquired a new stake in shares of Altimmune in the fourth quarter valued at about $65,000. Virtus Investment Advisers LLC lifted its stake in shares of Altimmune by 217.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 50,482 shares of the company’s stock worth $182,000 after buying an additional 34,568 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new position in shares of Altimmune in the fourth quarter worth about $36,000. 78.05% of the stock is owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.